Meeting
2021 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
Authors
Elizabeth Katherine Lee
Dana-Farber Cancer Institute, Boston, MA
Elizabeth Katherine Lee , Niya Xiong , Nabihah Tayob , Carolyn N. Krasner , Mary K. Buss , Susana M. Campos , Alexi A. Wright , Joyce F. Liu , Meghan Shea , Oladapo O. Yeku , Cesar Martin Castro , Rebecca L Porter , Elizabeth Stover , Sara Bouberhan , John William Moroney , Stephen A. Cannistra , Richard T. Penson , Gini F. Fleming , Ursula A. Matulonis , Panagiotis A. Konstantinopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT02912572
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5609)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5609
Abstract #
TPS5609
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2020 ASCO Virtual Scientific Program
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
First Author: Christian Marth
Poster
2017 ASCO Annual Meeting
Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer.
First Author: Panagiotis A. Konstantinopoulos
First Author: B.J. Rimel